mepolizumab

Home
Ligands
mepolizumab

GtoPdb Ligand ID: 7685

Synonyms: Nucala® | SB-240563

mepolizumab is an approved drug (EMA & FDA (2015))

Comment: The Nucala® brand of mepolizumab is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells.

View more information in the IUPHAR Pharmacology Education Project: mepolizumab

References
1. Bel EH, I Bernstein D, Bjermer L, Follows R, Bentley JH, Pouliquen I, Bradford E. (2020) Usability of mepolizumab single-use prefilled syringe for patient self-administration. J Asthma, 57 (7): 755-764. [PMID:31017022]
2. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators. (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med, 371 (13): 1189-97. [PMID:25199060]
3. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. (2003) Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med, 167 (2): 199-204. [PMID:12406833]
4. Hamelmann E, Gelfand EW. (1999) Role of IL-5 in the development of allergen-induced airway hyperresponsiveness. Int Arch Allergy Immunol, 120 (1): 8-16. [PMID:10529584]
5. Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER et al.. (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol, 108 (2): 250-7. [PMID:11496242]
6. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R et al.. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet, 356 (9248): 2144-8. [PMID:11191542]
7. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J. (2003) Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol, 111 (4): 714-9. [PMID:12704348]
8. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW et al.. (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med, 371 (13): 1198-207. [PMID:25199059]
9. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LA, Davis CB. (1999) Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther, 291 (3): 1060-7. [PMID:10565825]

References

1. Bel EH, I Bernstein D, Bjermer L, Follows R, Bentley JH, Pouliquen I, Bradford E. (2020)
Usability of mepolizumab single-use prefilled syringe for patient self-administration.
J Asthma, 57 (7): 755-764. [PMID:31017022]

2. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators. (2014)
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
N Engl J Med, 371 (13): 1189-97. [PMID:25199060]

3. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. (2003)
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Am J Respir Crit Care Med, 167 (2): 199-204. [PMID:12406833]

4. Hamelmann E, Gelfand EW. (1999)
Role of IL-5 in the development of allergen-induced airway hyperresponsiveness.
Int Arch Allergy Immunol, 120 (1): 8-16. [PMID:10529584]

5. Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER et al.. (2001)
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
J Allergy Clin Immunol, 108 (2): 250-7. [PMID:11496242]

6. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R et al.. (2000)
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.
Lancet, 356 (9248): 2144-8. [PMID:11191542]

7. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J. (2003)
Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.
J Allergy Clin Immunol, 111 (4): 714-9. [PMID:12704348]

8. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW et al.. (2014)
Mepolizumab treatment in patients with severe eosinophilic asthma.
N Engl J Med, 371 (13): 1198-207. [PMID:25199059]

9. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LA, Davis CB. (1999)
Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
J Pharmacol Exp Ther, 291 (3): 1060-7. [PMID:10565825]